Wellington Management Group LLP Has $312.49 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Wellington Management Group LLP lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 9.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,727,450 shares of the company's stock after buying an additional 903,683 shares during the period. Wellington Management Group LLP owned approximately 7.45% of Denali Therapeutics worth $312,491,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DNLI. GAMMA Investing LLC raised its holdings in shares of Denali Therapeutics by 879.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock worth $48,000 after acquiring an additional 1,847 shares during the period. CWM LLC increased its position in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company's stock worth $63,000 after purchasing an additional 654 shares during the last quarter. Quest Partners LLC acquired a new stake in Denali Therapeutics during the third quarter worth about $73,000. Assetmark Inc. raised its stake in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company's stock worth $111,000 after purchasing an additional 580 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock valued at $152,000 after purchasing an additional 920 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Trading Up 6.7 %

DNLI traded up $1.57 during trading hours on Friday, hitting $24.89. 513,278 shares of the company's stock were exchanged, compared to its average volume of 900,668. Denali Therapeutics Inc. has a 12-month low of $14.56 and a 12-month high of $33.33. The firm has a market cap of $3.58 billion, a P/E ratio of -9.02 and a beta of 1.35. The firm has a 50 day moving average of $26.76 and a 200 day moving average of $24.64.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period last year, the business earned ($0.72) EPS. As a group, research analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Insider Activity

In other news, CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. This represents a 14.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander O. Schuth sold 15,558 shares of Denali Therapeutics stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the transaction, the insider now owns 178,066 shares in the company, valued at $5,325,954.06. The trade was a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 86,578 shares of company stock worth $2,474,440 over the last three months. Corporate insiders own 7.90% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on DNLI shares. HC Wainwright restated a "buy" rating and set a $90.00 price target on shares of Denali Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group raised their target price on Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. JPMorgan Chase & Co. decreased their target price on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Cantor Fitzgerald cut shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, October 7th. Finally, Raymond James restated a "market perform" rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.90.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.